frequerqt intervals after an i.m. dose of 750 mg (1 patient) or 1500 mg (2 patients). In 7 patients bile was taken during cholecystectomy; 1-3 h after the first i.m. dose of 750-1500 mg (5 patients) or after a dose on the second day of treatment (2 patients).
Sputum was collected from 5 patients (all with chronic bronchitis in exacerbation with copious purulent sputum) on different days of treatment with 750 mg or 1500 mg i.m. 3 times daily, and at different times after a dose. Pieces of cancellous bone were removed during operation for hip fracture from 4 patients receiving cefuroxime 750 mg or 1500 mg i.m. thrice daily for 1 or 3 days. In 2 patients undergoing peritoneal dialysis, fluids were collected at suitable intervals after a dose of 1000 mg i.m. In one patient pleuritic fluid (transudate) was collected 4 h after an i.m. dose of 1500 mg and in one other patient cerebrospinal fluid (CSF) was taken 3 h after 1500 mg of cefuroxime i.m. Table 3 Serum levels of cefuroxime after the first dose of 1000 mg i.m. (n = 6) Concentrations (l.g/ml) and time (h) 
Urine
Mean concentrations in urine exceeded 1000l,g/ml in the first 4 h and 500 ,ug/ml up to 6 h at all dosages and were above 150 ,tg/ml up to 8 h when examined, i.e. after doses of 750 and 1000 mg (Table 5) . The mean recovery rates were 69.1 %, 82.0% and 83.2% of the injected quantity after the i.m. doses and 97.1 % after the i.v. doses. In patients I and 2 specimens were taken after 24 h of cefuroxime therapy. In the remainder only I dose was given. 
Bile
Concentrations of cefuroxime in T-tube drained bile reached a peak of 8.6 ,ug/ml 3 h after 750 mg i.m. and 30-32 ,ug/ml 4 h after 1500 mg i.m. in those patients studied. Bile obtained during operation from the gallbladder 1-3 h after the first dose of 750-1500 mg ranged from 2.3-9.5 jug/ml with higher values after higher dosages with the one inexplicable exception of a very low value (0.2 ,ug/ml) with a simultaneous high serum level (30.0 ,tg/ml, 1.5 h after a 1000 mg dose). There was no obstruction or purulence in the bile. Specimens obtained after 24 h treatment were much higher (16.5 ,ug/ml, Table 6 ).
Sputum
Levels of cefuroxime in sputum were not very high. During treatment with 750 mg i.m. three times daily they never exceeded 2.1 ,ug/ml and were often undetectable (Table 7) . At a dosage of 1500 mg i.m. three times daily, cefuroxime was almost always detectable but very rarely exceeded. (O'Callaghan et al. 1976) . With these data in mind bioavailability studies can be better evaluated. Serum concentrations were well above the MIC of susceptible pathogens for 4 h after injection of 500 mg i.m. and 1000 mg i.v. and for 6 h after 750 mg and 1000 mg i.m. The observed half life means that therapeutic levels may persist for this period of time without accumulation during 6 or 8 hourly regimens.
Urinary concentrations were very high at all dosages studied and levels above 150 ,ug/ml persisted for 8 h, enough to kill even moderately sensitive organisms. The high recovery rate after i.v. injection is an indication that the drug is excreted unchanged. Levels in bile were satisfactory. Even after 1 dose they were inhibitory for most pathogens, especially using the higher doses. Treatment for 24 h resulted in even higher levels.
Although levels of cefuroxime in sputum were not very high, the extremely low MIC of cefuroxime for H. influenza, (O'Callaghan et al. 1976) can justify optimism about therapeutic potential in exacerbations of chronic bronchitis. During our own clinical trial (Daikos et al. 1977 ) results in lower respiratory infections were very satisfactory.
Bone concentrations after 3 days of treatment were several fold above the MIC of Staphylococcus aureus. With 1500 mg three times daily levels were even above the MIC of methicillin-resistant strains. The number of our patients is admittedly small but we feel optimistic about treating bone infections with cefuroxime.
The measured concentrations in peritoneal fluid and pleural transudate were made in a small number of patients but the levels obtained were consistently high and certainly therapeutic. Infection of the corresponding cavities can therefore be expected to be successfully treated.
In ,ug/ml in most patients receiving 750-1500 mg i.m. Sputum levels were not impressive, remaining below 1-2 ,ug/ml after 750 mg i.m. three times daily and slightly higher in cases receiving 1500 mg i.m. three times daily. Bone concentrations after 1500 mg i.m. three times daily exceeded 10 ,ug/ml even from the second day of treatment but were lower after 750 mg i.m. three times daily. Levels in peritoneal dialysate and pleural fluid were therapeutic after i.m. dosages, but in one patient cefuroxime was not detected in CSF after 1500 mg i.m.
